Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
August 2020
-
Statement
Novartis appoints Marc Boutin as Global Head of Patient Engagement & Advocacy
Novartis has appointed Marc Boutin as Global Head of Patient Engagement & Advocacy. He will join Novartis no later than November 1, 2020.
-
Ensuring medicine supply to patients during COVID-19
Read how two sites within the Novartis Technical Operations (NTO) network ensured business continuity at scale and speed in the midst of the COVID-19 pandemic.
-
Media Release
Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication1 Chronic… -
Media Release
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1… -
Media Release
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously… -
Media Release
Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1 …
July 2020
-
Collaborating to explore new gene regulation therapies
Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.
-
Media Release
Novartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial… -
Statement
Choice with Responsibility: Reimagining how we work
-
Media Release
Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe
Sandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150… -
Media Release
New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus aflibercept
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept… -
Breaking a vicious cycle of inflammation
Novartis researchers aim to quash inflammation to treat chronic disease.
Pagination
- ‹ Previous page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- …
- 154
- › Next page
Test disclaimer...!!!